WO2001054668A1 - Pharmaceutical compositions comprising a hmg reductase inhibitor - Google Patents

Pharmaceutical compositions comprising a hmg reductase inhibitor Download PDF

Info

Publication number
WO2001054668A1
WO2001054668A1 PCT/GB2000/003014 GB0003014W WO0154668A1 WO 2001054668 A1 WO2001054668 A1 WO 2001054668A1 GB 0003014 W GB0003014 W GB 0003014W WO 0154668 A1 WO0154668 A1 WO 0154668A1
Authority
WO
WIPO (PCT)
Prior art keywords
tribasic
pharmaceutical composition
phosphate
salt
dihydroxyhept
Prior art date
Application number
PCT/GB2000/003014
Other languages
French (fr)
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001054668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UA2002021419A priority Critical patent/UA51853C2/en
Priority to SI200030065T priority patent/SI1223918T1/en
Priority to AU65800/00A priority patent/AU6580000A/en
Priority to EP00953283A priority patent/EP1223918B1/en
Priority to IL14787000A priority patent/IL147870A/en
Priority to DK00953283T priority patent/DK1223918T3/en
Priority to EEP200200052A priority patent/EE04990B1/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to MEP-338/08A priority patent/MEP33808A/en
Priority to APAP/P/2002/002409A priority patent/AP1449A/en
Priority to MEP-2008-338A priority patent/ME00191B/en
Priority to DE60001371T priority patent/DE60001371T2/en
Priority to AT00953283T priority patent/ATE232088T1/en
Publication of WO2001054668A1 publication Critical patent/WO2001054668A1/en
Priority to IS6254A priority patent/IS1940B/en
Priority to HR20020097A priority patent/HRP20020097B1/en
Priority to BG106393A priority patent/BG65234B1/en
Priority to HK02108790.3A priority patent/HK1047052A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (and referred to hereinafter as "the Agent"), in particular the sodium and calcium salts, and especially the calcium salt, bis[(E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid] calcium salt (of the formula I hereinafter).
  • the Agent is disclosed as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase
  • HMG CoA reductase in European Patent Application , Publication No. 0521471 and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444 and is useful in the treatment of hypercholesterolemia, hyperlipidproteinemia and atherosclerosis.
  • a problem associated with the Agent is that it undergoes degradation under certain conditions. This makes it difficult to formulate the product and provide a pharmaceutical composition with adequate storage life.
  • the major degradation products formed are the corresponding (3R, 5S) lactone (hereinafter referred to as “the lactone”) and an oxidation product (hereinafter referred to as "B2") in which the hydroxy group adjacent to the carbon- carbon double bond is oxidised to a ketone functionality. It is therefore important to find a pharmaceutical composition of the Agent which remains stable over a prolonged period. It is also preferable that such a composition has a good flow rate to assist processing into unit dosage forms for oral administration, for example into tablets, and good disintegration and dissolution characteristics when processed into tablets for oral administration, which tablets can be in different dosage strengths. It is also desirable that such tablets are of a convenient size for ease of administration.
  • a first aspect of the invention comprises a pharmaceutical composition comprising the Agent and a tribasic phosphate salt in which the cation is multivalent.
  • a second aspect of the invention comprises the use of a tribasic phosphate salt in which the cation is multivalent to stabilise the Agent.
  • a tribasic phosphate salt in which the cation is multivalent includes, for example, tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate. Tribasic calcium phosphate is especially preferred.
  • the ratio of tribasic phosphate salt to Agent in the pharmaceutical composition is, for example, within the range of 1 :80 to 50: 1 by weight, for example 1 :50 to 50: 1 by weight, such as 1:10 to 10:1 by weight, and more particularly 1:5 to 10:1 by weight.
  • the pharmaceutical composition of the invention is formulated into an oral dosage form, such as a tablet.
  • a further aspect of the invention comprises a pharmaceutical composition comprising the Agent, a tribasic phosphate salt in which the cation is multivalent, and one or more fillers, binders, disintegrants or lubricants.
  • a still further aspect of the invention relates to a pharmaceutical composition for oral administration comprising the Agent, one or more fillers, one or more binders, one or more disintegrants, one or more lubricants and a tribasic phosphate salt in which the cation is multivalent.
  • Suitable fillers include, for example, lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g. microcrystalline cellulose, cellulose), calcium sulfate, xylitol and lactitol.
  • Suitable binders include, for example, polyvinylpyrrolidone, lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatin and sodium alginate.
  • Suitable disintegrants include, for example, crosscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycollate, corn starch, microcrystalline cellulose, hydroxypropyl methylcellulose and hydroxypropyl cellulose.
  • Suitable lubricants include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hydrogenated vegetable oils, mineral oil, polyethylene glycols and sodium stearyl fumarate.
  • Additional conventional excipients which may be added include preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents or glidants.
  • the Agent will be present in an amount within the range of 1 to 50%, and preferably from 1 to 20% (especially 2 to 15%) by weight of the composition.
  • the tribasic phosphate salt such as tribasic calcium phosphate
  • the tribasic phosphate salt will be present in an amount within the range of 1 to 50%, for example 1 to 25%, such as 1 to 20%, and particularly 5 to 18% by weight.
  • one or more fillers will be present in an amount 30 to 90% by weight.
  • one or more binders will be present in an amount 2 to 90% by weight.
  • one or more disintegrants will be present in an amount 2 to 10%, and especially 4 to 6% by weight.
  • a particular excipient may act as both a binder and a filler, or as a binder, a filler and a disintegrant.
  • the combined amount of filler, binder and disintegrant comprises, for example, 70 to 90% by weight of the composition.
  • one or more lubricants will be present in an amount 0.5 to 3%, and especially 1 to 2% by weight.
  • compositions of the invention include, for example, those comprising the Agent, tribasic calcium phosphate and excipients selected from lactose, mannitol, microcrystalline cellulose, povidone, crospovidone, sodium starch glycollate and magnesium stearate.
  • compositions of the invention include, for example, compositions comprising the Agent, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate; compositions comprising the Agent, povidone, tribasic calcium phosphate, microcrystalline cellulose, mannitol, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate; compositions comprising the Agent, tribasic calcium phosphate, crospovidone, microcrystalline cellulose, lactose and magnesium stearate, and compositions comprising the Agent, povidone, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch glycollate, magnesium stearate and butylated hydroxytoluene. Where lactose and microcrystalline cellulose are used, these are preferably present in the ratio of about 1 :1 to 3:1 by weight.
  • compositions of the invention which are of particular interest include, for example, the specific embodiments set out hereinafter in the accompanying Examples.
  • the pharmaceutical composition of the invention may be prepared, using standard techniques and manufacturing processes generally known in the art, for example by dry blending the components.
  • the Agent for example tribasic calcium phosphate
  • one or more fillers for example tribasic calcium phosphate
  • one or more binders for example tribasic calcium phosphate
  • disintegrants as well as other additional excipients if desired are blended together.
  • the components of the blend prior to blending, or the blend itself may be passed through a mesh screen, for example a 400-700 um mesh screen.
  • a lubricant which may also be screened, is then added to the blend and blending continued until a homogeneous mixture is obtained.
  • the mixture is then compressed into tablets.
  • a wet granulation technique can be employed.
  • the Agent the tribasic phosphate salt, one or more fillers, one or more binders and a portion of a disintegrant, as well as other additional excipients if desired, are blended together, for example by using a granulator, and the powder blend is granulated with a small volume of purified water. The granulate is dried and passed though a mill. The remainder of the disintegrant and a lubricant are added to the milled granulation and after blending the resultant homogeneous mixture is compressed into tablets. It will be appreciated that modifications of the dry blending and wet granulation techniques, including the order of addition of the components and their screening and blending prior to compression into tablets, may be carried out according to principles well known in the art.
  • a tablet coating may then be applied, for example by spray-coating, with a water- based film coating formulation.
  • the coating may comprise, for example, lactose, hydroxypropyl methylcellulose, triacetin, titanium dioxide and ferric oxides. Coating ingredient combinations are commercially available, such as those described in the Examples hereinafter.
  • the coating may comprise, for example, 0.5 to 10% by weight of the tablet composition, particularly 1 to 6%, and preferably 2 to 3%. Coatings containing ferric oxides are especially preferred as they reduce the rate of formation of photodegradation products of the Agent.
  • a further aspect of the present invention comprises a method of preparing a stabilised pharmaceutical composition which comprises admixing the Agent with a tribasic phosphate salt in which the cation is multivalent.
  • a further aspect of the present invention comprises a method of producing a stabilised pharmaceutical composition which comprises incorporating a tribasic phosphate salt in which the cation is multivalent in a pharmaceutical composition containing the Agent.
  • compositions wherein the Agent is the calcium salt of formula I, are intended to illustrate the invention without being limitative in any way.
  • the Agent microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, tribasic calcium phosphate, and butylated hydroxytoluene were blended together for 10 minutes.
  • Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes.
  • the resulting homogeneous mixture was compressed into tablets.
  • the tablets were stored at 70°C/80% relative humidity for one week. After one week there was found to be only 0.1 l%w/w of the oxidation product B2 formed and only 0.50%w/w of the lactone.
  • a similar formulation in which 20.0 mg of tribasic calcium phosphate was replaced by 20.0 mg of dibasic calcium phosphate, 0.23%w/w of B2 was formed and 15.61%w/w of the lactone.
  • the Agent 2.50 mg Povidone 2.50 mg
  • the Agent povidone, mannitol, microcrystalline cellulose, butylated hydroxytoluene, tribasic calcium phosphate and sodium starch glycollate (in the amounts given above) were blended for 5 to 60 minutes.
  • Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes.
  • the resulting homogeneous mixture was compressed into tablets.
  • the compressed tablets were coated by spraying with a mixture of hydroxypropyl methylcellulose, polyethylene glycol 400, titanium dioxide and ferric oxide (sold as Spectrablend by Warner- Jenkinson) and water in a coating pan.
  • the weight gain provided by the coating was 1 to 6%w/w, and preferably 2 to 3 %w/w.
  • Tribasic calcium phosphate 5.66 mg
  • the Agent and crospovidone were blended together for 5 minutes and the blend then passed through a 400-700um screen. A small portion of the microcrystalline cellulose was passed through the screen afterwards.
  • the screened material was blended with the other ingredients, excluding the lubricant, for 10 minutes.
  • Magnesium stearate was passed through a #40 mesh (425 um) screen and added to the blend and the mixture was blended for a further 3 minutes.
  • the resulting homogeneous mixture was compressed into tablets.
  • the compressed tablets were coated by spraying with a mixture of lactose monohydrate, hydroxypropyl methylcellulose, triacetin and ferric oxide (sold as Opadry II by Colorcon) and water in a coating pan.
  • the weight gain provided by the coating 1 to 6%w/w, and preferably 2 to 3%w/w.
  • the tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.19%w/w of the oxidation product B2 had formed and only 2.71%w/w of the lactone.
  • a portion of the tribasic calcium phosphate and butylated hydroxytoluene were blended for 30 seconds in a bag.
  • the Agent, povidone, remainder of the tribasic calcium phosphate, microcrystalline cellulose, lactose monohydrate, tribasic calcium phophate/butylated hydroxytoluene mixture and a portion of the sodium starch glycolate were blended in a granulator for 30 seconds.
  • the powder blend was granulated with purified water for 1 minute at the addition rate of 70 mg/tablet/minute.
  • the granulation is dried in a fluidized bed drier at 50°C until the loss on drying is less than 2% w/w.
  • the dried granulation is passed through a mill (e.g. Comil).
  • the milled granulation and the remainder of the sodium starch glycolate was blended for approximately 5 minutes.
  • Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes.
  • the resulting homogeneous mixture was compressed into tablets.
  • the tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.23 %w/w of the oxidation product B2 had formed and only 0.28%w/w of the lactone.
  • a similar formulation in which 20.0 mg of tribasic calcium phosphate was replaced by 20.0 mg of dibasic calcium phosphate, 0.19 %w/w of B2 was formed and 28.15 %w/w of the lactone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns a pharmaceutical composition comprising the HMG CoA reductase inhibitor (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, which remains stable over a prolonged period.

Description

PHARMACEUTICAL COMPOSITIONS COMPRI SI NG A HMG REDUCTASE I NHIB ITOR
The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (and referred to hereinafter as "the Agent"), in particular the sodium and calcium salts, and especially the calcium salt, bis[(E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid] calcium salt (of the formula I hereinafter). The Agent is disclosed as an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase
(HMG CoA reductase) in European Patent Application , Publication No. 0521471 and in Bioorganic and Medicinal Chemistry, (1997), 5(2), 437-444 and is useful in the treatment of hypercholesterolemia, hyperlipidproteinemia and atherosclerosis.
A problem associated with the Agent is that it undergoes degradation under certain conditions. This makes it difficult to formulate the product and provide a pharmaceutical composition with adequate storage life. The major degradation products formed are the corresponding (3R, 5S) lactone (hereinafter referred to as "the lactone") and an oxidation product (hereinafter referred to as "B2") in which the hydroxy group adjacent to the carbon- carbon double bond is oxidised to a ketone functionality. It is therefore important to find a pharmaceutical composition of the Agent which remains stable over a prolonged period. It is also preferable that such a composition has a good flow rate to assist processing into unit dosage forms for oral administration, for example into tablets, and good disintegration and dissolution characteristics when processed into tablets for oral administration, which tablets can be in different dosage strengths. It is also desirable that such tablets are of a convenient size for ease of administration.
Pharmaceutical formulations of certain 7-substituted-3,5-dihydroxy-6-heptenoic acid salts, which are HMG CoA reductase inhibitors, are disclosed in UK Patent 2262229. These formulations require the presence of an alkaline medium (such as a carbonate or bicarbonate) capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition. We have now discovered a novel pharmaceutical composition of the Agent which has advantageous properties and which solves one or more of the problems associated with formulation of the Agent.
Accordingly, a first aspect of the invention comprises a pharmaceutical composition comprising the Agent and a tribasic phosphate salt in which the cation is multivalent.
A second aspect of the invention comprises the use of a tribasic phosphate salt in which the cation is multivalent to stabilise the Agent.
A tribasic phosphate salt in which the cation is multivalent includes, for example, tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate. Tribasic calcium phosphate is especially preferred.
The ratio of tribasic phosphate salt to Agent in the pharmaceutical composition is, for example, within the range of 1 :80 to 50: 1 by weight, for example 1 :50 to 50: 1 by weight, such as 1:10 to 10:1 by weight, and more particularly 1:5 to 10:1 by weight.
Preferably the pharmaceutical composition of the invention is formulated into an oral dosage form, such as a tablet. Accordingly a further aspect of the invention comprises a pharmaceutical composition comprising the Agent, a tribasic phosphate salt in which the cation is multivalent, and one or more fillers, binders, disintegrants or lubricants. A still further aspect of the invention relates to a pharmaceutical composition for oral administration comprising the Agent, one or more fillers, one or more binders, one or more disintegrants, one or more lubricants and a tribasic phosphate salt in which the cation is multivalent.
Suitable fillers include, for example, lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g. microcrystalline cellulose, cellulose), calcium sulfate, xylitol and lactitol.
Suitable binders include, for example, polyvinylpyrrolidone, lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatin and sodium alginate.
Suitable disintegrants include, for example, crosscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycollate, corn starch, microcrystalline cellulose, hydroxypropyl methylcellulose and hydroxypropyl cellulose. Suitable lubricants include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hydrogenated vegetable oils, mineral oil, polyethylene glycols and sodium stearyl fumarate.
Additional conventional excipients which may be added include preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents or glidants.
Other suitable fillers, binders, disintegrants, lubricants and additional excipients which may be used are described in Handbook of Pharmaceutical Excipients, 2nd Edition, American Pharmaceutical Association; The Theory and Practice of Industrial Pharmacy, 2nd Edition, Lachman, Leon, 1976; Pharmaceutical Dosage Forms: Tablets Volume 1, 2nd Edition, Lieberman, Hebert A., et al. 1989; Modern Pharmaceutics, Banker, Gilbert and Rhodes, Christopher T, 1979; and Remington 's Pharmaceutical Sciences, 15th Edition, 1975.
Typically the Agent will be present in an amount within the range of 1 to 50%, and preferably from 1 to 20% (especially 2 to 15%) by weight of the composition.
Typically the tribasic phosphate salt, such as tribasic calcium phosphate, will be present in an amount within the range of 1 to 50%, for example 1 to 25%, such as 1 to 20%, and particularly 5 to 18% by weight.
Typically one or more fillers will be present in an amount 30 to 90% by weight.
Typically one or more binders will be present in an amount 2 to 90% by weight.
Typically one or more disintegrants will be present in an amount 2 to 10%, and especially 4 to 6% by weight.
It will be appreciated that a particular excipient may act as both a binder and a filler, or as a binder, a filler and a disintegrant. Typically the combined amount of filler, binder and disintegrant comprises, for example, 70 to 90% by weight of the composition.
Typically one or more lubricants will be present in an amount 0.5 to 3%, and especially 1 to 2% by weight.
Preferred compositions of the invention include, for example, those comprising the Agent, tribasic calcium phosphate and excipients selected from lactose, mannitol, microcrystalline cellulose, povidone, crospovidone, sodium starch glycollate and magnesium stearate. Preferred independent compositions of the invention include, for example, compositions comprising the Agent, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate; compositions comprising the Agent, povidone, tribasic calcium phosphate, microcrystalline cellulose, mannitol, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate; compositions comprising the Agent, tribasic calcium phosphate, crospovidone, microcrystalline cellulose, lactose and magnesium stearate, and compositions comprising the Agent, povidone, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch glycollate, magnesium stearate and butylated hydroxytoluene. Where lactose and microcrystalline cellulose are used, these are preferably present in the ratio of about 1 :1 to 3:1 by weight.
Compositions of the invention which are of particular interest include, for example, the specific embodiments set out hereinafter in the accompanying Examples.
The pharmaceutical composition of the invention may be prepared, using standard techniques and manufacturing processes generally known in the art, for example by dry blending the components. For example, the Agent, the tribasic phosphate salt (for example tribasic calcium phosphate), one or more fillers, one or more binders and one or more disintegrants, as well as other additional excipients if desired are blended together. The components of the blend prior to blending, or the blend itself, may be passed through a mesh screen, for example a 400-700 um mesh screen. A lubricant, which may also be screened, is then added to the blend and blending continued until a homogeneous mixture is obtained. The mixture is then compressed into tablets. Alternatively, a wet granulation technique can be employed. For example, the Agent, the tribasic phosphate salt, one or more fillers, one or more binders and a portion of a disintegrant, as well as other additional excipients if desired, are blended together, for example by using a granulator, and the powder blend is granulated with a small volume of purified water. The granulate is dried and passed though a mill. The remainder of the disintegrant and a lubricant are added to the milled granulation and after blending the resultant homogeneous mixture is compressed into tablets. It will be appreciated that modifications of the dry blending and wet granulation techniques, including the order of addition of the components and their screening and blending prior to compression into tablets, may be carried out according to principles well known in the art.
A tablet coating may then be applied, for example by spray-coating, with a water- based film coating formulation. The coating may comprise, for example, lactose, hydroxypropyl methylcellulose, triacetin, titanium dioxide and ferric oxides. Coating ingredient combinations are commercially available, such as those described in the Examples hereinafter. The coating may comprise, for example, 0.5 to 10% by weight of the tablet composition, particularly 1 to 6%, and preferably 2 to 3%. Coatings containing ferric oxides are especially preferred as they reduce the rate of formation of photodegradation products of the Agent.
A further aspect of the present invention comprises a method of preparing a stabilised pharmaceutical composition which comprises admixing the Agent with a tribasic phosphate salt in which the cation is multivalent. A further aspect of the present invention comprises a method of producing a stabilised pharmaceutical composition which comprises incorporating a tribasic phosphate salt in which the cation is multivalent in a pharmaceutical composition containing the Agent.
The following pharmaceutical compositions, wherein the Agent is the calcium salt of formula I, are intended to illustrate the invention without being limitative in any way.
Example 1
The Agent 2.50 mg
Tribasic calcium phosphate 20.0 mg
Microcrystalline cellulose 47.0 mg Lactose monohydrate 47.0 mg
Sodium starch glycollate 3.00 mg
Butylated hydroxytoluene 0.05 mg
Magnesium stearate 1.00 mg
The Agent, microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, tribasic calcium phosphate, and butylated hydroxytoluene were blended together for 10 minutes. Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes. The resulting homogeneous mixture was compressed into tablets. The tablets were stored at 70°C/80% relative humidity for one week. After one week there was found to be only 0.1 l%w/w of the oxidation product B2 formed and only 0.50%w/w of the lactone. By comparison a similar formulation in which 20.0 mg of tribasic calcium phosphate was replaced by 20.0 mg of dibasic calcium phosphate, 0.23%w/w of B2 was formed and 15.61%w/w of the lactone.
Example 2
The Agent 2.50 mg Povidone 2.50 mg
Tribasic calcium phosphate 20.0 mg
Microcrystalline cellulose 47.0 mg
Mannitol 47.0 mg
Sodium starch glycollate 3.00 mg Butylated hydroxytoluene 0.05 mg
Magnesium stearate 1.00 mg
The Agent, povidone, mannitol, microcrystalline cellulose, butylated hydroxytoluene, tribasic calcium phosphate and sodium starch glycollate (in the amounts given above) were blended for 5 to 60 minutes. Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes. The resulting homogeneous mixture was compressed into tablets. The compressed tablets were coated by spraying with a mixture of hydroxypropyl methylcellulose, polyethylene glycol 400, titanium dioxide and ferric oxide (sold as Spectrablend by Warner- Jenkinson) and water in a coating pan. The weight gain provided by the coating was 1 to 6%w/w, and preferably 2 to 3 %w/w.
The tablets were stored at 70°C/80% relative humidity for one week. After one week there was found to be only 0.06%w/w of the oxidation product B2 formed and only 2.22%w/w of the lactone. Example 3
The Agent 2.60 mg
Crospovidone 3.75 mg Tribasic calcium phosphate 5.66 mg
Microcrystalline cellulose 15.5 mg
Lactose monohydrate 46.5 mg
Magnesium stearate 0.94 mg
The Agent and crospovidone were blended together for 5 minutes and the blend then passed through a 400-700um screen. A small portion of the microcrystalline cellulose was passed through the screen afterwards. The screened material was blended with the other ingredients, excluding the lubricant, for 10 minutes. Magnesium stearate was passed through a #40 mesh (425 um) screen and added to the blend and the mixture was blended for a further 3 minutes. The resulting homogeneous mixture was compressed into tablets. The compressed tablets were coated by spraying with a mixture of lactose monohydrate, hydroxypropyl methylcellulose, triacetin and ferric oxide (sold as Opadry II by Colorcon) and water in a coating pan. The weight gain provided by the coating 1 to 6%w/w, and preferably 2 to 3%w/w. The tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.19%w/w of the oxidation product B2 had formed and only 2.71%w/w of the lactone.
Example 4
The Agent 2.50 mg
Povidone 2.50 mg
Tribasic calcium phosphate 20.0 mg
Microcrystalline cellulose 34.5 mg
Lactose monohydrate 34.0 mg Sodium starch glycollate 6.00 mg
Magnesium stearate 1.00 mg Butylated hydroxytoluene 0.05 mg
A portion of the tribasic calcium phosphate and butylated hydroxytoluene were blended for 30 seconds in a bag. The Agent, povidone, remainder of the tribasic calcium phosphate, microcrystalline cellulose, lactose monohydrate, tribasic calcium phophate/butylated hydroxytoluene mixture and a portion of the sodium starch glycolate were blended in a granulator for 30 seconds. The powder blend was granulated with purified water for 1 minute at the addition rate of 70 mg/tablet/minute. The granulation is dried in a fluidized bed drier at 50°C until the loss on drying is less than 2% w/w. The dried granulation is passed through a mill (e.g. Comil). The milled granulation and the remainder of the sodium starch glycolate was blended for approximately 5 minutes. Magnesium stearate was screened through a #40 mesh (425 um) screen and added to the blend and blending continued for a further three minutes. The resulting homogeneous mixture was compressed into tablets.
The tablets were stored at 70°C/80% relative humidity for one week. After this time only 0.23 %w/w of the oxidation product B2 had formed and only 0.28%w/w of the lactone. By comparison a similar formulation in which 20.0 mg of tribasic calcium phosphate was replaced by 20.0 mg of dibasic calcium phosphate, 0.19 %w/w of B2 was formed and 28.15 %w/w of the lactone.
Figure imgf000009_0001
Formula I

Claims

CLAIMSWhat we claim is:-
1. A pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient and a tribasic phosphate salt in which the cation is multivalent.
2. A pharmaceutical composition as claimed in claim 1 wherein the tribasic phosphate salt in which the cation is multivalent is selected from tribasic calcium phosphate, tribasic magnesium phosphate and tribasic aluminium phosphate.
3. A pharmaceutical composition as claimed in claim 1 or 2 wherein the tribasic phosphate salt in which the cation is multivalent is tribasic calcium phosphate.
4. A pharmaceutical composition as claimed in any of claims 1 to 3 wherein the ratio of the tribasic phosphate salt to the active ingredient is in the range of 1:80 to 50:1 by weight.
5. A pharmaceutical composition as claimed in any preceding claim additionally comprising one or more fillers, binders, disintegrants or lubricants.
6. A pharmaceutical composition for oral administration comprising (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, one or more fillers, one or more binders, one or more disintegrants, one or more lubricants and a tribasic phosphate salt in which the cation is multivalent.
7. A pharmaceutical composition as claimed in claim 6 wherein the active ingredient is present in an amount 1 to 80% by weight of the composition.
8. A pharmaceutical composition as claimed in claim 6 or 7 wherein the tribasic phosphate salt is present in an amount 1 to 50% by weight of the composition.
9. A pharmaceutical composition as claimed in claim 6, 7 or 8 wherein the filler is 5 present in an amount 30 to 90% by weight of the composition.
10. A pharmaceutical composition as claimed in any of claims 6 to 9 wherein the binder is present in an amount 2 to 90% by weight of the composition.
10 11. A pharmaceutical composition as claimed in any of claims 6 to 10 wherein the disintegrant is present in an amount 2 to 10% by weight of the composition.
12. A pharmaceutical composition as claimed in any of claims 6 to 11 wherein the lubricant is present in an amount 0.5 to 3% by weight.
15
13. A pharmaceutical composition as claimed in claim 6 comprising (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, microcrystalline cellulose, lactose, sodium starch 0 glycollate, butylated hydroxytoluene and magnesium stearate.
14. A pharmaceutical composition as claimed in claim 6 comprising (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[memyl(memylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active 5 ingredient, tribasic calcium phosphate, povidone, microcrystalline cellulose, mannitol, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate.
15. A pharmaceutical composition as claimed in claim 6 comprising (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- 0 dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, crospovidone, microcrystalline cellulose, lactose and magnesium stearate.
16. A pharmaceutical composition as claimed in claim 6 comprising (E)-7-[4-(4-
5 fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5- dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof as the active ingredient, tribasic calcium phosphate, povidone, microcrystalline cellulose, lactose, sodium starch glycollate, butylated hydroxytoluene and magnesium stearate.
10 17. A pharmaceutical composition as claimed in any preceding claim wherein the active ingredient is the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid.
18. The use of a tribasic phosphate salt in which the cation is multivalent to stabilise the
15 compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin- 5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
19. The use as claimed in claim 18 wherein the the tribasic phosphate salt in which the cation is multivalent is selected from tribasic calcium phosphate, tribasic magnesium
20 phosphate and tribasic aluminium phosphate.
20. The use as claimed in claim 18 or 19 wherein the the tribasic phosphate salt in which the cation is multivalent is tribasic calcium phosphate.
25 21. A method of producing a stabilised pharmaceutical composition which comprises incorporating a tribasic phosphate salt in which the cation is multivalent in a pharmaceutical composition containing the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
30
PCT/GB2000/003014 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor WO2001054668A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
UA2002021419A UA51853C2 (en) 2000-01-26 2000-04-08 Pharmaceutical composition comprising hmg reductase inhibitor, stabilization of inhibitor with tribasic phosphate and method for obtaining stabilized pharmaceutical composition
AT00953283T ATE232088T1 (en) 2000-01-26 2000-08-04 PHARMACEUTICAL COMPOSITIONS CONTAINING A HMG-COA REDUCTASE INHIBITOR
MEP-2008-338A ME00191B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
EP00953283A EP1223918B1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
IL14787000A IL147870A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising (e)-7 [4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)-amino [pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof and a tribasic phosphate salt in which the cation is multivalent
DK00953283T DK1223918T3 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EEP200200052A EE04990B1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions containing an HMG reductase inhibitor, their use and method of preparation
SI200030065T SI1223918T1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
MEP-338/08A MEP33808A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
APAP/P/2002/002409A AP1449A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor.
AU65800/00A AU6580000A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
DE60001371T DE60001371T2 (en) 2000-01-26 2000-08-04 PHARMACEUTICAL COMPOSITIONS CONTAINING AN HMG-COA REDUCTASE INHIBITOR
IS6254A IS1940B (en) 2000-01-26 2002-01-29 Pharmaceutical formulations containing HMG reducing enzyme inhibitors
HR20020097A HRP20020097B1 (en) 2000-01-26 2002-01-30 Pharmaceutical compositions comprising a hmg reductase inhibitor
BG106393A BG65234B1 (en) 2000-01-26 2002-02-06 Pharmaceutical composition comprising a hmg reductase inhibitor
HK02108790.3A HK1047052A1 (en) 2000-01-26 2002-12-03 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0001621.1 2000-01-26
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
WO2001054668A1 true WO2001054668A1 (en) 2001-08-02

Family

ID=9884259

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2000/003014 WO2001054668A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
PCT/GB2000/003017 WO2001054669A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003017 WO2001054669A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Country Status (48)

Country Link
US (2) US6548513B1 (en)
EP (6) EP1251831A1 (en)
JP (3) JP3267960B2 (en)
KR (3) KR100388713B1 (en)
CN (3) CN1149997C (en)
AP (2) AP1449A (en)
AR (3) AR023624A1 (en)
AT (3) AT412063B (en)
AU (5) AU781269C (en)
BE (2) BE1013413A3 (en)
BG (4) BG65234B1 (en)
BR (2) BR0003365A (en)
CA (3) CA2315141C (en)
CH (2) CH700184B1 (en)
CL (1) CL2007001807A1 (en)
CR (3) CR6568A (en)
CZ (3) CZ290167B6 (en)
DE (3) DE10038110B4 (en)
DK (3) DK178242B1 (en)
EE (3) EE04990B1 (en)
ES (2) ES2171123B1 (en)
FI (3) FI111806B (en)
FR (2) FR2795324B1 (en)
GB (3) GB0001621D0 (en)
HK (6) HK1036935A1 (en)
HR (3) HRP20020097B1 (en)
HU (2) HUP0003111A3 (en)
IL (4) IL147870A (en)
IS (3) IS1940B (en)
IT (2) ITTO20000780A1 (en)
ME (4) ME00202B (en)
MY (2) MY123650A (en)
NL (2) NL1015859C2 (en)
NO (4) NO312434B1 (en)
NZ (2) NZ519774A (en)
PL (2) PL196808B1 (en)
PT (3) PT1223918E (en)
RS (1) RS50201B (en)
RU (2) RU2206324C1 (en)
SE (2) SE523471C2 (en)
SI (1) SI1223918T1 (en)
SK (2) SK11792000A3 (en)
TR (3) TR200201888T2 (en)
TW (2) TW553749B (en)
UA (2) UA51853C2 (en)
WO (2) WO2001054668A1 (en)
YU (1) YU52902A (en)
ZA (2) ZA200003998B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014872A1 (en) 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US6841554B2 (en) 2000-02-15 2005-01-11 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
EP1594474A2 (en) 2003-02-12 2005-11-16 LEK Pharmaceuticals D.D. Coated particles and pharmaceutical dosage forms
KR100698333B1 (en) * 2000-01-26 2007-03-23 아스트라제네카 아베 Pharmaceutical compositions
WO2008035128A1 (en) * 2006-09-18 2008-03-27 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2010140992A1 (en) 2009-06-03 2010-12-09 Mahmut Bilgic Stable pharmaceutical compositions containing rosuvastatin calcium
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
WO2012064307A1 (en) 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin
US8632807B2 (en) 2011-05-20 2014-01-21 Astrazeneca Uk Limited Pharmaceutical composition
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
US10398694B2 (en) 2014-11-11 2019-09-03 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable to light

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
AU2001253287B2 (en) † 2000-04-10 2005-04-28 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
KR20040026705A (en) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 Processes for preparing calcium salt forms of statins
WO2004016262A1 (en) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
HUE044279T2 (en) * 2003-09-12 2019-10-28 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (en) * 2003-12-02 2011-05-15 Teva Pharma REFERENCE STANDARD FOR CHARACTERIZATION OF ROSUVASTATIN
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
PE20060003A1 (en) * 2004-03-12 2006-03-01 Smithkline Beecham Plc POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING
AU2005240137B2 (en) * 2004-05-04 2010-04-15 Innophos, Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (en) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 Composition for treating hyperlipemia
JP2007508379A (en) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Method for preparing rosuvastatin comprising a TEMPO-mediated oxidation step
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
MX2007010138A (en) * 2005-02-22 2007-09-27 Teva Pharma Preparation of rosuvastatin.
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
MX2008001597A (en) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Novel formulations comprising fenofibrate and a statin, and related methods of treatment.
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
PL1944029T3 (en) * 2005-10-31 2012-05-31 Kowa Co Pharmaceutical preparation having excellent photostability
JP5235676B2 (en) * 2005-12-20 2013-07-10 レツク・フアーマシユーテイカルズ・デー・デー (E) -7- [4- (4-Fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl]-(3R, 5S) -3,5-dihydroxyhepta Pharmaceutical composition comprising 6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
CA2681449A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
CN101336920B (en) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 Stable medicine combination
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
HUE035402T2 (en) * 2008-06-27 2018-05-02 Krka Tovarna Zdravil D D Novo Mesto Pharmaceutical composition comprising a statin
MX2010013834A (en) * 2008-06-27 2011-02-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium.
PL386051A1 (en) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
MX344885B (en) * 2008-11-10 2017-01-10 Psicofarma S A De C V Process for obtaining a composition of rosuvastatin calcium and product obtained.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (en) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stable rosuvastatin compositions
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
EA201270269A1 (en) 2009-08-13 2012-09-28 Синтон Б.В. PHARMACEUTICAL TABLET CONTAINING ROSUVASTATIN CALCIUM
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (en) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 Tablet containing Rosuvastatin calcium and preparation process thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (en) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Processes for preparing piperazinium salts of sildenafil-analogues and use thereof
JP5988963B2 (en) * 2011-04-12 2016-09-07 沢井製薬株式会社 Pitavastatin-containing preparation and method for producing the same
RU2508109C2 (en) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating lipid storage disease
ES2903149T3 (en) * 2012-05-14 2022-03-31 Shionogi & Co Preparation containing 6,7-unsaturated 7-carbamoylmorphinan derivative
AR091706A1 (en) * 2012-07-11 2015-02-25 Teva Pharma LAQUINIMOD FORMULATIONS WITHOUT ALKALINIZING AGENTS
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (en) 2013-04-25 2014-11-28 Antibiotice S.A. Stable pharmaceutical composition with amorphous rosuvastatin calcium
RU2547574C2 (en) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Hypolipidemic dosage form and method for preparing it
KR101597004B1 (en) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
JP2016169198A (en) * 2015-03-13 2016-09-23 大原薬品工業株式会社 Tablets comprising rosuvastatin calcium
JP6095176B2 (en) * 2015-04-24 2017-03-15 大原薬品工業株式会社 Film-coated tablets with improved photostability of rosuvastatin calcium
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (en) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 A kind of pharmaceutical composition comprising rosuvastain calcium and preparation method thereof
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
EP3634382A4 (en) 2017-06-09 2021-07-07 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (en) * 2017-11-24 2018-02-22 共和薬品工業株式会社 Pharmaceutical composition
CN112274487A (en) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 Rosuvastatin calcium pharmaceutical preparation
CN110638743B (en) * 2019-10-25 2023-03-28 乐普制药科技有限公司 Composition containing brivaracetam
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
GB2262229A (en) * 1991-12-12 1993-06-16 Sandoz Ltd Stabilised hmg-coa reductase inhibitor compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (en) 1988-02-25 1989-08-28 Bayer Ag SUBSTITUTED PYRIMIDINES.
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (en) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabilized solid chemical agents
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ATE178794T1 (en) * 1993-01-19 1999-04-15 Warner Lambert Co STABILIZED ORAL COMPOSITION CONTAINING THE COMPOUND CI-981 AND METHOD
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DK0814782T3 (en) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Pharmaceutical preparation stabilized with a basic agent
DE69713948D1 (en) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rapidly releasing pH-independent solid dosage forms containing cisapride
WO1999062560A1 (en) 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (en) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (en) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd USE OF AN AGENT THAT DECREASES CHOLESTEROL
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001054688A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
GB2262229A (en) * 1991-12-12 1993-06-16 Sandoz Ltd Stabilised hmg-coa reductase inhibitor compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRAUL A ET AL: "ZD-4522: Hypolipidemic HMG-CoA reductase inhibitor.", DRUGS OF THE FUTURE, vol. 24, no. 5, May 1999 (1999-05-01), pages 511 - 513, XP000882032, ISSN: 0377-8282 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005202392B2 (en) * 2000-01-26 2008-11-20 Astrazeneca Ab Pharmaceutical compositions
AU2005202392C1 (en) * 2000-01-26 2016-06-02 Astrazeneca Ab Pharmaceutical compositions
KR100698333B1 (en) * 2000-01-26 2007-03-23 아스트라제네카 아베 Pharmaceutical compositions
US6841554B2 (en) 2000-02-15 2005-01-11 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
US7129352B2 (en) 2000-02-15 2006-10-31 Astrazeneca Ab Crystalline salts of 7-′4-(4-fluorophenyl) -6-isopropyl-2-′methyl (methylsulfonyl) amino!pyrimidin-5-yl!- (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid
WO2004014872A1 (en) 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
US9149460B2 (en) 2003-02-12 2015-10-06 Lek Pharmaceuticals D.D. Coated particles and pharmaceutical dosage forms
US9907757B2 (en) 2003-02-12 2018-03-06 Lek Pharmaceuticals D.D. Coated particles and pharmaceutical dosage forms
EP1594474A2 (en) 2003-02-12 2005-11-16 LEK Pharmaceuticals D.D. Coated particles and pharmaceutical dosage forms
EA014451B1 (en) * 2006-09-18 2010-12-30 Рихтер Гедеон Нирт. Pharmaceutical compositions containing rosuvastatin calcium
WO2008035128A1 (en) * 2006-09-18 2008-03-27 Richter Gedeon Nyrt. Pharmaceutical compositions containing rosuvastatin calcium
WO2009095934A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
US8765947B2 (en) 2008-05-27 2014-07-01 Changzhou Pharmaceutical Factory Preparation method of Rosuvastatin calcium and its intermediates
WO2009143776A1 (en) 2008-05-27 2009-12-03 常州制药厂有限公司 Preparation method of rosuvastatin calcium and its intermediates
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2010140992A1 (en) 2009-06-03 2010-12-09 Mahmut Bilgic Stable pharmaceutical compositions containing rosuvastatin calcium
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
WO2012064307A1 (en) 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin
US8632807B2 (en) 2011-05-20 2014-01-21 Astrazeneca Uk Limited Pharmaceutical composition
US10028953B2 (en) 2011-05-20 2018-07-24 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
US10398694B2 (en) 2014-11-11 2019-09-03 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable to light
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
WO2017194432A1 (en) 2016-05-09 2017-11-16 Adamed Sp. Z O.O. Pharmaceutical composition

Also Published As

Publication number Publication date
PT1223918E (en) 2003-06-30
FR2795324A1 (en) 2000-12-29
AP2002002409A0 (en) 2002-03-31
ZA200003997B (en) 2000-08-14
PL196808B1 (en) 2008-02-29
TR200200270T2 (en) 2002-06-21
KR100388713B1 (en) 2003-06-25
DE60001371D1 (en) 2003-03-13
SK11782000A3 (en) 2001-12-03
RS50201B (en) 2009-07-15
ME00202B (en) 2010-10-10
FI20001749A (en) 2001-07-27
HUP0003111A3 (en) 2003-03-28
NL1015859C2 (en) 2001-10-16
AR023624A1 (en) 2002-09-04
CA2315141A1 (en) 2001-07-26
HRP20020632B1 (en) 2010-12-31
DK1223918T3 (en) 2003-04-28
FI121589B (en) 2011-01-31
GB2358583A (en) 2001-08-01
FI20001750A0 (en) 2000-08-04
IS1940B (en) 2004-07-16
CA2313783C (en) 2002-03-12
HK1047052A1 (en) 2003-02-07
EE200200052A (en) 2003-04-15
AU5184200A (en) 2001-08-02
HK1048950A1 (en) 2003-04-25
DK200001170A (en) 2001-01-27
CH691347A5 (en) 2001-07-13
SE523471C2 (en) 2004-04-20
GB0019029D0 (en) 2000-09-27
BG66168B1 (en) 2011-10-31
IL147870A (en) 2003-10-31
HK1200368A1 (en) 2015-08-07
FR2804025B1 (en) 2002-08-23
YU52902A (en) 2006-01-16
DE10038110A1 (en) 2001-08-23
MY123650A (en) 2006-05-31
CA2639407C (en) 2011-09-13
ITTO20000779A0 (en) 2000-08-04
EP2774609A1 (en) 2014-09-10
PL341855A1 (en) 2001-07-30
SE0002827D0 (en) 2000-08-04
JP2007182452A (en) 2007-07-19
FI20001749A0 (en) 2000-08-04
ZA200003998B (en) 2000-08-14
HK1036934A1 (en) 2002-01-25
JP2001206877A (en) 2001-07-31
BE1013414A5 (en) 2001-12-04
IL187416A0 (en) 2008-02-09
IL150513A (en) 2012-12-31
NZ531474A (en) 2007-04-27
FR2795324B1 (en) 2002-05-17
CZ299105B6 (en) 2008-04-23
HUP0003110A3 (en) 2003-02-28
TR200701171T2 (en) 2007-04-24
CA2639407A1 (en) 2001-07-26
CZ20002884A3 (en) 2001-09-12
SI1223918T1 (en) 2003-06-30
SE0002826D0 (en) 2000-08-04
ITTO20000780A1 (en) 2000-11-04
AU2005202392A1 (en) 2005-06-30
AP1879A (en) 2008-08-14
HU0003110D0 (en) 2000-10-28
UA77156C2 (en) 2006-11-15
EP1223918B1 (en) 2003-02-05
ATE232088T1 (en) 2003-02-15
EE200200411A (en) 2003-12-15
TWI228050B (en) 2005-02-21
BR0003365A (en) 2001-09-18
YU5202A (en) 2004-12-31
ATA13612000A (en) 2004-02-15
NO20003968L (en) 2001-07-27
HRP20020097A2 (en) 2002-06-30
HUP0003110A2 (en) 2001-05-28
IS6254A (en) 2002-01-29
NO327675B1 (en) 2009-09-07
BG66159B1 (en) 2011-09-30
FI20105657A (en) 2010-06-10
HRP20080525A2 (en) 2008-12-31
CH700184B1 (en) 2010-07-15
AU738074B2 (en) 2001-09-06
RU2264210C2 (en) 2005-11-20
IS6480A (en) 2002-07-23
BG110353A (en) 2009-09-30
DK200001171A (en) 2001-07-27
EP1223918A1 (en) 2002-07-24
DE10038108A1 (en) 2001-08-02
GB0019028D0 (en) 2000-09-27
HU0003111D0 (en) 2000-10-28
BR0003364A (en) 2001-09-18
SE523481C2 (en) 2004-04-20
AT412062B (en) 2004-09-27
CR6568A (en) 2004-03-05
SK11792000A3 (en) 2001-12-03
AT412063B (en) 2004-09-27
EP1251831A1 (en) 2002-10-30
IS8620A (en) 2007-03-07
CA2313783A1 (en) 2000-10-16
ES2171123B1 (en) 2003-11-16
EE05221B1 (en) 2009-10-15
ITTO20000779A1 (en) 2002-02-04
AU781269C (en) 2006-11-30
KR20000072135A (en) 2000-12-05
JP3267960B2 (en) 2002-03-25
PL341853A1 (en) 2001-01-29
NO20003967D0 (en) 2000-08-04
CN1319396A (en) 2001-10-31
SE0002826L (en) 2001-07-27
EE04990B1 (en) 2008-04-15
AU2000264559A1 (en) 2001-08-07
AP1449A (en) 2005-07-28
ES2155043A1 (en) 2001-04-16
HU222578B1 (en) 2003-08-28
SK283872B6 (en) 2004-03-02
AU2005202392B2 (en) 2008-11-20
CN101028268A (en) 2007-09-05
DK178242B1 (en) 2015-09-28
PT102503B (en) 2004-02-27
PT102504A (en) 2001-07-31
AU5184100A (en) 2001-08-02
DE60001371T2 (en) 2004-01-22
HK1036935A1 (en) 2002-01-25
FI121365B (en) 2010-10-29
CN1282581A (en) 2001-02-07
DE10038110B4 (en) 2006-06-29
NL1015858C2 (en) 2001-07-27
FI20001750A (en) 2001-07-27
NO20071303L (en) 2001-07-27
WO2001054669A1 (en) 2001-08-02
HRP20020632A2 (en) 2004-12-31
AU6580000A (en) 2001-08-07
CL2007001807A1 (en) 2008-01-18
CZ20002883A3 (en) 2000-10-11
ES2155043B1 (en) 2001-12-01
HK1040936A1 (en) 2002-06-28
UA51853C2 (en) 2002-12-16
CN1149997C (en) 2004-05-19
PT102503A (en) 2000-12-29
EE200900047A (en) 2011-04-15
MEP33708A (en) 2010-10-10
CA2315141C (en) 2009-08-18
AR025055A1 (en) 2002-11-06
TW553749B (en) 2003-09-21
IS2805B (en) 2012-09-15
HK1040936B (en) 2010-06-11
IL147870A0 (en) 2002-08-14
BE1013413A3 (en) 2001-12-04
NO312434B1 (en) 2002-05-13
AU2005202392C1 (en) 2016-06-02
HRP20020097B1 (en) 2010-12-31
RU2002122752A (en) 2004-03-10
TR200201888T2 (en) 2002-11-21
AU781269B2 (en) 2005-05-12
MEP33808A (en) 2010-10-10
RU2206324C1 (en) 2003-06-20
NL1015859A1 (en) 2001-07-27
CN100528161C (en) 2009-08-19
AP2002002591A0 (en) 2002-09-30
BG106393A (en) 2002-07-31
HUP0003111A2 (en) 2002-02-28
GB0001621D0 (en) 2000-03-15
CZ298411B6 (en) 2007-09-26
EP2018853A1 (en) 2009-01-28
FI111806B (en) 2003-09-30
EP2266540A1 (en) 2010-12-29
US6548513B1 (en) 2003-04-15
JP4800467B2 (en) 2011-10-26
ME00191B (en) 2010-10-10
NZ519774A (en) 2004-04-30
NO2010005I1 (en) 2010-05-03
NO327554B1 (en) 2009-08-10
SE0002827L (en) 2001-07-27
ATA13602000A (en) 2004-02-15
KR20010077840A (en) 2001-08-20
FR2804025A1 (en) 2001-07-27
JP4800988B2 (en) 2011-10-26
KR20030036492A (en) 2003-05-09
CZ290167B6 (en) 2002-06-12
NO20003967L (en) 2001-07-27
KR100698333B1 (en) 2007-03-23
BG65234B1 (en) 2007-09-28
ES2171123A1 (en) 2002-08-16
AR060248A2 (en) 2008-06-04
EP2133070A1 (en) 2009-12-16
CR6687A (en) 2005-07-18
CR10114A (en) 2008-08-21
GB2358583B (en) 2002-02-06
NO20003968D0 (en) 2000-08-04
EE05586B1 (en) 2012-10-15
IL150513A0 (en) 2003-02-12
US6316460B1 (en) 2001-11-13
GB2358582A (en) 2001-08-01
BG106926A (en) 2003-04-30
GB2358582B (en) 2004-09-29
JP2001206847A (en) 2001-07-31
MY122707A (en) 2006-04-29

Similar Documents

Publication Publication Date Title
EP1223918B1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
MXPA00007656A (en) Pharmaceutical compositions
MXPA00007659A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-52/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000953283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 147870

Country of ref document: IL

Ref document number: IN/PCT/2002/00112/MU

Country of ref document: IN

Ref document number: 1200200098

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: P20020097A

Country of ref document: HR

Ref document number: 516911

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/00270

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 106393

Country of ref document: BG

Kind code of ref document: A

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2002 2002103603

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000953283

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000953283

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 516911

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 516911

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: JP